JERUSALEM & PARSIPPANY, N.J. & INCHEON, South Korea–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Celltrion, Inc., (KRX KRX:068270) and Celltrion Healthcare, Co., Ltd. (KRX KOSDAQ:091990), today announced that TRUXIMA® (rituximab-abbs) injection is the first biosimilar to the reference product Rituxan®1 (rituximab) now available in the United States with a full oncology label. TRUXIMA is currently indicated for the treatment of adult patients with non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL): Non-Hodgkin’s Lymphoma (NHL) Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHLas a single agent Previously untreated follicular,

This content is restricted to site members. If you are an existing user, please log in. New users may register too.